Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: An analysis using the propensity score

Hirotoshi Ebinuma, Hidetsugu Saito, Shinichiro Tada, Nobuhiro Nakamoto, Tazuko Ohishi, Satoshi Tsunematsu, Naoki Kumagai, Kanji Tsuchimoto, Nobuhiro Tsukada, Yasutaka Inagaki, Yoshinori Horie, Masahiko Takahashi, Kazuhiro Atsukawa, Yukishige Okamura, Takanori Kanai, Toshifumi Hibi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose Peginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in 50%. However, a trend of decreasing SVR in the older patients has been reported. In the present study, we verified this trend of treatment efficacy in older patients using the propensity score (PS). Methods We conducted a survey of 327 patients with CHC (genotype 1 and high viral loads) who were treated with PEG-IFN and RBV for 48 weeks. The SVR rate was compared between patients =60 and <60 years of age. Because backgrounds of these patients differed considerably, we verified this efficacy between the older (n = 102) and younger (n = 102) patients matched for gender, body weight, platelets (PLT), and red blood cell (RBC) counts using PS. Results The total SVR rate was 42.9% (161/327); this rate decreased with increasing age and was lower in the older patients (C60 years: 41.5%, <60 years: 54.3%, P = 0.0245). Moreover, younger age was a significant factor for SVR. After correction by PS, the SVR in older patients remained significantly lower (C60 years: 43.1%, <60 years: 57.8%, P = 0.0497). In addition, RBC counts and hemoglobin (Hgb) concentrations, as well as RBV adherence in the older patients, decreased with this treatment, although there were no significant differences in pretreatment RBC and Hgb levels. Conclusions The analysis using PS indicated that RBV adherence in the older patients decreased even if they did not have lower pretreatment RBC and Hgb levels.

Original languageEnglish
Pages (from-to)744-752
Number of pages9
JournalHepatology International
Volume6
Issue number4
DOIs
Publication statusPublished - 2012 Oct

Fingerprint

Propensity Score
Ribavirin
Chronic Hepatitis C
Therapeutics
Hemoglobins
Erythrocyte Count
Viral Load
Erythrocytes
Genotype
Hepacivirus
Blood Platelets
Body Weight

Keywords

  • Chronic hepatitis C
  • Propensity score
  • Ribavirin adherence
  • The combination treatment of peginterferon and ribavirin
  • The elderly patients

ASJC Scopus subject areas

  • Hepatology

Cite this

Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C : An analysis using the propensity score. / Ebinuma, Hirotoshi; Saito, Hidetsugu; Tada, Shinichiro; Nakamoto, Nobuhiro; Ohishi, Tazuko; Tsunematsu, Satoshi; Kumagai, Naoki; Tsuchimoto, Kanji; Tsukada, Nobuhiro; Inagaki, Yasutaka; Horie, Yoshinori; Takahashi, Masahiko; Atsukawa, Kazuhiro; Okamura, Yukishige; Kanai, Takanori; Hibi, Toshifumi.

In: Hepatology International, Vol. 6, No. 4, 10.2012, p. 744-752.

Research output: Contribution to journalArticle

Ebinuma, H, Saito, H, Tada, S, Nakamoto, N, Ohishi, T, Tsunematsu, S, Kumagai, N, Tsuchimoto, K, Tsukada, N, Inagaki, Y, Horie, Y, Takahashi, M, Atsukawa, K, Okamura, Y, Kanai, T & Hibi, T 2012, 'Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: An analysis using the propensity score', Hepatology International, vol. 6, no. 4, pp. 744-752. https://doi.org/10.1007/s12072-011-9312-9
Ebinuma, Hirotoshi ; Saito, Hidetsugu ; Tada, Shinichiro ; Nakamoto, Nobuhiro ; Ohishi, Tazuko ; Tsunematsu, Satoshi ; Kumagai, Naoki ; Tsuchimoto, Kanji ; Tsukada, Nobuhiro ; Inagaki, Yasutaka ; Horie, Yoshinori ; Takahashi, Masahiko ; Atsukawa, Kazuhiro ; Okamura, Yukishige ; Kanai, Takanori ; Hibi, Toshifumi. / Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C : An analysis using the propensity score. In: Hepatology International. 2012 ; Vol. 6, No. 4. pp. 744-752.
@article{cdf180c8e0c6495c8d0fcafd068c7bd7,
title = "Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: An analysis using the propensity score",
abstract = "Purpose Peginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in 50{\%}. However, a trend of decreasing SVR in the older patients has been reported. In the present study, we verified this trend of treatment efficacy in older patients using the propensity score (PS). Methods We conducted a survey of 327 patients with CHC (genotype 1 and high viral loads) who were treated with PEG-IFN and RBV for 48 weeks. The SVR rate was compared between patients =60 and <60 years of age. Because backgrounds of these patients differed considerably, we verified this efficacy between the older (n = 102) and younger (n = 102) patients matched for gender, body weight, platelets (PLT), and red blood cell (RBC) counts using PS. Results The total SVR rate was 42.9{\%} (161/327); this rate decreased with increasing age and was lower in the older patients (C60 years: 41.5{\%}, <60 years: 54.3{\%}, P = 0.0245). Moreover, younger age was a significant factor for SVR. After correction by PS, the SVR in older patients remained significantly lower (C60 years: 43.1{\%}, <60 years: 57.8{\%}, P = 0.0497). In addition, RBC counts and hemoglobin (Hgb) concentrations, as well as RBV adherence in the older patients, decreased with this treatment, although there were no significant differences in pretreatment RBC and Hgb levels. Conclusions The analysis using PS indicated that RBV adherence in the older patients decreased even if they did not have lower pretreatment RBC and Hgb levels.",
keywords = "Chronic hepatitis C, Propensity score, Ribavirin adherence, The combination treatment of peginterferon and ribavirin, The elderly patients",
author = "Hirotoshi Ebinuma and Hidetsugu Saito and Shinichiro Tada and Nobuhiro Nakamoto and Tazuko Ohishi and Satoshi Tsunematsu and Naoki Kumagai and Kanji Tsuchimoto and Nobuhiro Tsukada and Yasutaka Inagaki and Yoshinori Horie and Masahiko Takahashi and Kazuhiro Atsukawa and Yukishige Okamura and Takanori Kanai and Toshifumi Hibi",
year = "2012",
month = "10",
doi = "10.1007/s12072-011-9312-9",
language = "English",
volume = "6",
pages = "744--752",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C

T2 - An analysis using the propensity score

AU - Ebinuma, Hirotoshi

AU - Saito, Hidetsugu

AU - Tada, Shinichiro

AU - Nakamoto, Nobuhiro

AU - Ohishi, Tazuko

AU - Tsunematsu, Satoshi

AU - Kumagai, Naoki

AU - Tsuchimoto, Kanji

AU - Tsukada, Nobuhiro

AU - Inagaki, Yasutaka

AU - Horie, Yoshinori

AU - Takahashi, Masahiko

AU - Atsukawa, Kazuhiro

AU - Okamura, Yukishige

AU - Kanai, Takanori

AU - Hibi, Toshifumi

PY - 2012/10

Y1 - 2012/10

N2 - Purpose Peginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in 50%. However, a trend of decreasing SVR in the older patients has been reported. In the present study, we verified this trend of treatment efficacy in older patients using the propensity score (PS). Methods We conducted a survey of 327 patients with CHC (genotype 1 and high viral loads) who were treated with PEG-IFN and RBV for 48 weeks. The SVR rate was compared between patients =60 and <60 years of age. Because backgrounds of these patients differed considerably, we verified this efficacy between the older (n = 102) and younger (n = 102) patients matched for gender, body weight, platelets (PLT), and red blood cell (RBC) counts using PS. Results The total SVR rate was 42.9% (161/327); this rate decreased with increasing age and was lower in the older patients (C60 years: 41.5%, <60 years: 54.3%, P = 0.0245). Moreover, younger age was a significant factor for SVR. After correction by PS, the SVR in older patients remained significantly lower (C60 years: 43.1%, <60 years: 57.8%, P = 0.0497). In addition, RBC counts and hemoglobin (Hgb) concentrations, as well as RBV adherence in the older patients, decreased with this treatment, although there were no significant differences in pretreatment RBC and Hgb levels. Conclusions The analysis using PS indicated that RBV adherence in the older patients decreased even if they did not have lower pretreatment RBC and Hgb levels.

AB - Purpose Peginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in 50%. However, a trend of decreasing SVR in the older patients has been reported. In the present study, we verified this trend of treatment efficacy in older patients using the propensity score (PS). Methods We conducted a survey of 327 patients with CHC (genotype 1 and high viral loads) who were treated with PEG-IFN and RBV for 48 weeks. The SVR rate was compared between patients =60 and <60 years of age. Because backgrounds of these patients differed considerably, we verified this efficacy between the older (n = 102) and younger (n = 102) patients matched for gender, body weight, platelets (PLT), and red blood cell (RBC) counts using PS. Results The total SVR rate was 42.9% (161/327); this rate decreased with increasing age and was lower in the older patients (C60 years: 41.5%, <60 years: 54.3%, P = 0.0245). Moreover, younger age was a significant factor for SVR. After correction by PS, the SVR in older patients remained significantly lower (C60 years: 43.1%, <60 years: 57.8%, P = 0.0497). In addition, RBC counts and hemoglobin (Hgb) concentrations, as well as RBV adherence in the older patients, decreased with this treatment, although there were no significant differences in pretreatment RBC and Hgb levels. Conclusions The analysis using PS indicated that RBV adherence in the older patients decreased even if they did not have lower pretreatment RBC and Hgb levels.

KW - Chronic hepatitis C

KW - Propensity score

KW - Ribavirin adherence

KW - The combination treatment of peginterferon and ribavirin

KW - The elderly patients

UR - http://www.scopus.com/inward/record.url?scp=84874113827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874113827&partnerID=8YFLogxK

U2 - 10.1007/s12072-011-9312-9

DO - 10.1007/s12072-011-9312-9

M3 - Article

AN - SCOPUS:84874113827

VL - 6

SP - 744

EP - 752

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 4

ER -